Technical Analysis for TCON - TRACON Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade D 0.54 0.00% 0.00
TCON closed unchanged on Friday, August 16, 2019, on 13 percent of normal volume. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Up
See historical TCON trend table...

Date Alert Name Type % Chg
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Stochastic Reached Overbought Strength 0.00%
Weak + Overbought Other 0.00%
Wide Bands Range Expansion 0.00%
Overbought Stochastic Strength 0.00%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Pocket Pivot Bullish Swing Setup 0.00%
Wide Bands Range Expansion 0.00%
Up 3 Days in a Row Strength 0.00%
Up 4 Days in a Row Strength 0.00%

Older signals for TCON ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
TRACON Pharmaceuticals, Inc., a biopharmaceutical company, focused on the development and commercialization of novel targeted therapeutics for cancer, age-related macular degeneration, and fibrotic diseases. Its lead product candidate is TRC105, which is in Phase II clinical trials for oncology indications, including soft tissue sarcoma, renal cell carcinoma, glioblastoma, and hepatocellular carcinoma. The company is planning for clinical trials of TRC105, including a Phase II clinical trial in patients with breast cancer and hepatocellular carcinoma, a Phase I clinical trial in patients with colorectal cancer, and a Phase I clinical trial in patients with lung cancer, as well as conducting preclinical studies of TRC105 in AMD. In addition, the company product candidates comprise TRC205, an anti-endoglin antibody that is in preclinical stage for the treatment of fibrotic diseases; and TRC102, a small molecule, which is in clinical development for the treatment of lung cancer and glioblastoma. The company was formerly known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in March 2005. TRACON Pharmaceuticals, Inc. was founded in 2004 and is headquartered in San Diego, California.
Medicine Health Biopharmaceutical Cancer Drugs Clinical Trial Breast Cancer Colorectal Cancer Glioblastoma Targeted Therapy Age Related Macular Degeneration Hepatocellular Carcinoma Lung Cancer Renal Cell Carcinoma Therapeutics For Cancer Fibrotic Diseases Ros1 Transgene Sa
Is TCON a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 2.35
52 Week Low 0.4
Average Volume 207,722
200-Day Moving Average 0.9155
50-Day Moving Average 0.5694
20-Day Moving Average 0.4777
10-Day Moving Average 0.4649
Average True Range 0.0531
ADX 21.28
+DI 18.972
-DI 13.6302
Chandelier Exit (Long, 3 ATRs ) 0.4228
Chandelier Exit (Short, 3 ATRs ) 0.5593
Upper Bollinger Band 0.5711
Lower Bollinger Band 0.3843
Percent B (%b) 0.83
BandWidth 39.10404
MACD Line -0.0189
MACD Signal Line -0.0369
MACD Histogram 0.018
Fundamentals Value
Market Cap 8.99 Million
Num Shares 16.7 Million
EPS -1.75
Price-to-Earnings (P/E) Ratio -0.31
Price-to-Sales 17.03
Price-to-Book 2.65
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.61
Resistance 3 (R3) 0.61 0.58 0.60
Resistance 2 (R2) 0.58 0.56 0.58 0.60
Resistance 1 (R1) 0.56 0.55 0.54 0.56 0.59
Pivot Point 0.53 0.53 0.52 0.53 0.53
Support 1 (S1) 0.51 0.51 0.50 0.52 0.49
Support 2 (S2) 0.48 0.50 0.48 0.48
Support 3 (S3) 0.46 0.48 0.48
Support 4 (S4) 0.47